FDA Classifies Vaginitis Germ Detection Device as Safe
Published Date: 8/21/2025
Rule
Summary
The FDA is officially putting a new test that spots germs causing vaginitis and bacterial vaginosis into a safer, middle-level category called Class II. This means the device will follow special safety rules, making sure it works well and is safe to use. This change helps patients get better access to these helpful tests faster, without extra red tape, and it affects companies making or selling these devices starting now.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Vaginitis/BV Test Reclassified to Class II
The FDA has classified tests that detect nucleic acid sequences from microorganisms associated with vaginitis and bacterial vaginosis into Class II (special controls). The Agency says this classification provides a reasonable assurance of safety and effectiveness and will enhance patients' access to these tests by reducing regulatory burdens.
Reduced Regulatory Burden for Manufacturers
The FDA's reclassification of the nucleic-acid test for vaginitis and bacterial vaginosis to Class II is intended to reduce regulatory burdens on makers and sellers of these devices. The rule affects companies making or selling these devices starting now according to the order.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in